Depression – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Depression – Pipeline Review, H1 2017’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Depression

– The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Depression therapeutics and enlists all their major and minor projects

– The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Depression

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AB Science SA

Acadia Pharmaceuticals Inc

Adamed Sp z oo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Alkermes Plc

Allergan Plc

Alvogen Korea Co Ltd

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Angelini Group

Angita BV

Araim Pharmaceuticals Inc

AstraZeneca Plc

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

BioLite Inc

Bionomics Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calico LLC

Celgene Corp

Celon Pharma SA

Cerecor Inc

Clera Inc

Delpor Inc

Domain Therapeutics SA

Eisai Co Ltd

Eli Lilly and Company

Evotec AG

F. Hoffmann-La Roche Ltd

Fabre-Kramer Pharmaceuticals Inc

FPRT Bio Inc

GlaxoSmithKline Plc

GliaCure Inc

H. Lundbeck A/S

Heptares Therapeutics Ltd

Hua Medicine (Shanghai) Ltd

Hyundai Pharmaceutical Co Ltd

Impel NeuroPharma Inc

INSYS Therapeutics Inc

Intas Pharmaceuticals Ltd

Intra-Cellular Therapies Inc

INVENT Pharmaceuticals Inc

Johnson & Johnson

KemPharm Inc

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Luye Pharma Group Ltd

Mapi Pharma Ltd

Mapreg SAS

Medlab Clinical Ltd

Meta-IQ ApS

Methylation Sciences Inc

miCure Therapeutics Ltd

Mitsubishi Tanabe Pharma Corp

Navya Biologicals Pvt Ltd

Neuralstem Inc

Neurocrine Biosciences Inc

NeuroNascent Inc

NeurOp Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

nLife Therapeutics SL

Omeros Corp

Orexigen Therapeutics Inc

Otsuka Holdings Co Ltd

Pfizer Inc

Pherin Pharmaceuticals Inc

Polleo Pharma Ltd

Protagenic Therapeutics Inc

Relmada Therapeutics Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Saniona AB

SK Biopharmaceuticals Co Ltd

Sound Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Supernus Pharmaceuticals Inc

Suven Life Sciences Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Company Ltd

Tetra Discovery Partners LLC

Trevena Inc

TRImaran Pharma Inc

VistaGen Therapeutics Inc

Zhejiang Huahai Pharmaceutical Co Ltd

Zogenix Inc

Zysis Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Depression - Overview 8

Depression - Therapeutics Development 9

Depression - Therapeutics Assessment 33

Depression - Companies Involved in Therapeutics Development 49

Depression - Drug Profiles 97

Depression - Dormant Projects 427

Depression - Discontinued Products 441

Depression - Product Development Milestones 446

Appendix 456

List of Tables

List of Tables

Number of Products under Development for Depression, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Depression – Pipeline by 4D Pharma PLC, H1 2017

Depression – Pipeline by AB Science SA, H1 2017

Depression – Pipeline by Acadia Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Adamed Sp z oo, H1 2017

Depression – Pipeline by Addex Therapeutics Ltd, H1 2017

Depression – Pipeline by Aequus Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Alkermes Plc, H1 2017

Depression – Pipeline by Allergan Plc, H1 2017

Depression – Pipeline by Alvogen Korea Co Ltd, H1 2017

Depression – Pipeline by Amorsa Therapeutics Inc, H1 2017

Depression – Pipeline by Anavex Life Sciences Corp, H1 2017

Depression – Pipeline by Angelini Group, H1 2017

Depression – Pipeline by Angita BV, H1 2017

Depression – Pipeline by Araim Pharmaceuticals Inc, H1 2017

Depression – Pipeline by AstraZeneca Plc, H1 2017

Depression – Pipeline by Avanir Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Axsome Therapeutics Inc, H1 2017

Depression – Pipeline by Azevan Pharmaceuticals Inc, H1 2017

Depression – Pipeline by BioCrea GmbH, H1 2017

Depression – Pipeline by BioLite Inc, H1 2017

Depression – Pipeline by Bionomics Ltd, H1 2017

Depression – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Depression – Pipeline by Bristol-Myers Squibb Company, H1 2017

Depression – Pipeline by Calico LLC, H1 2017

Depression – Pipeline by Celgene Corp, H1 2017

Depression – Pipeline by Celon Pharma SA, H1 2017

Depression – Pipeline by Cerecor Inc, H1 2017

Depression – Pipeline by Clera Inc, H1 2017

Depression – Pipeline by Delpor Inc, H1 2017

Depression – Pipeline by Domain Therapeutics SA, H1 2017

Depression – Pipeline by Eisai Co Ltd, H1 2017

Depression – Pipeline by Eli Lilly and Company, H1 2017

Depression – Pipeline by Evotec AG, H1 2017

Depression – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Depression – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017

Depression – Pipeline by FPRT Bio Inc, H1 2017

Depression – Pipeline by GlaxoSmithKline Plc, H1 2017

Depression – Pipeline by GliaCure Inc, H1 2017

Depression – Pipeline by H. Lundbeck A/S, H1 2017

Depression – Pipeline by Heptares Therapeutics Ltd, H1 2017

Depression – Pipeline by Hua Medicine (Shanghai) Ltd, H1 2017

Depression – Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Depression – Pipeline by Impel NeuroPharma Inc, H1 2017

Depression – Pipeline by INSYS Therapeutics Inc, H1 2017

Depression – Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Depression – Pipeline by Intra-Cellular Therapies Inc, H1 2017

Depression – Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Johnson & Johnson, H1 2017

Depression – Pipeline by KemPharm Inc, H1 2017

Depression – Pipeline by Lead Discovery Center GmbH, H1 2017

Depression – Pipeline by Les Laboratoires Servier SAS, H1 2017

Depression – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Depression – Pipeline by Luye Pharma Group Ltd, H1 2017

Depression – Pipeline by Mapi Pharma Ltd, H1 2017

Depression – Pipeline by Mapreg SAS, H1 2017

Depression – Pipeline by Medlab Clinical Ltd, H1 2017

Depression – Pipeline by Meta-IQ ApS, H1 2017

Depression – Pipeline by Methylation Sciences Inc, H1 2017

Depression – Pipeline by miCure Therapeutics Ltd, H1 2017

Depression – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Depression – Pipeline by Navya Biologicals Pvt Ltd, H1 2017

Depression – Pipeline by Neuralstem Inc, H1 2017

Depression – Pipeline by Neurocrine Biosciences Inc, H1 2017

Depression – Pipeline by NeuroNascent Inc, H1 2017

Depression – Pipeline by NeurOp Inc, H1 2017

Depression – Pipeline by Newron Pharmaceuticals SpA, H1 2017

Depression – Pipeline by Nippon Chemiphar Co Ltd, H1 2017

Depression – Pipeline by nLife Therapeutics SL, H1 2017

Depression – Pipeline by Omeros Corp, H1 2017

Depression – Pipeline by Orexigen Therapeutics Inc, H1 2017

Depression – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Depression – Pipeline by Pfizer Inc, H1 2017

Depression – Pipeline by Pherin Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Polleo Pharma Ltd, H1 2017

Depression – Pipeline by Protagenic Therapeutics Inc, H1 2017

Depression – Pipeline by Relmada Therapeutics Inc, H1 2017

Depression – Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Richter Gedeon Nyrt, H1 2017

Depression – Pipeline by Sage Therapeutics Inc, H1 2017

Depression – Pipeline by Saniona AB, H1 2017

Depression – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Depression – Pipeline by Sound Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Depression – Pipeline by Supernus Pharmaceuticals Inc, H1 2017

Depression – Pipeline by Suven Life Sciences Ltd, H1 2017

Depression – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017

Depression – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Depression – Pipeline by Tetra Discovery Partners LLC, H1 2017

Depression – Pipeline by Trevena Inc, H1 2017

Depression – Pipeline by TRImaran Pharma Inc, H1 2017

Depression – Pipeline by VistaGen Therapeutics Inc, H1 2017

Depression – Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd, H1 2017

Depression – Pipeline by Zogenix Inc, H1 2017

Depression – Pipeline by Zysis Ltd, H1 2017

Depression – Dormant Projects, H1 2017

Depression – Dormant Projects, H1 2017 (Contd..1), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..2), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..3), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..4), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..5), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..6), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..7), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..8), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..9), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..10), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..11), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..12), H1 2017

Depression – Dormant Projects, H1 2017 (Contd..13), H1 2017

Depression – Discontinued Products, H1 2017

Depression – Discontinued Products, H1 2017 (Contd..1), H1 2017

Depression – Discontinued Products, H1 2017 (Contd..2), H1 2017

Depression – Discontinued Products, H1 2017 (Contd..3), H1 2017

Depression – Discontinued Products, H1 2017 (Contd..4), H1 2017

List of Figures

List of Figures

Number of Products under Development for Depression, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports